IPH AEN

Peptide bioregulation of reparative osteogenesis and osseointegration by IPH AEN leads to optimization of bone repair after surgery, suggesting significant improvements in bone healing and management. This peptide increases the production of collagen and hyaluronic acid by 67%, which enhances the reparative properties of cartilage by 41%, making it an effective means of combating joint and bone diseases.

The positive effects of the IPH AEN peptide in normalizing the functions of bone and cartilage tissue demonstrate increased cell stability and improved regenerative abilities. Stimulation of gene expression associated with bone and cartilage development increases by 19%, highlighting its therapeutic potential for tissue regeneration, reducing the need for surgery.

In addition, the IPH AEN peptide increases the expression of the COL2A1 gene by 16% and p53 protein by 55%, providing antitumor properties and reducing the development of tumor diseases by 45%.

The synergistic effect of IPH AEN peptide and amino acids in culture shows beneficial effects in tissue engineering and regenerative medicine. The peptide complex has a wide range of prophylactic applications; its scientifically proven properties and statistical data make it valuable for the prevention, restoration, and maintenance of joint and bone functions. More detailed research results can be found in the official scientific publications of IDEAL PHARMA PEPTIDE.